Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2013

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions

Bone Marrow Transplantation RecipientCord Blood Transplant RecipientHematopoietic Cell Transplantation Recipient

Interventions

DRUG

Eltrombopag Olamine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01927731 - Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant | Biotech Hunter | Biotech Hunter